BioCentury | May 17, 2019
Financial News

Tools4Patient raises €4M to refine, expand placebo response analytics

...consider raising another round in about 18 months to support a broader expansion. Another company, Biometheus LLC...
...website has been taken down, and an inquiry to its former CEO went unreturned (see "Biometheus...
BioCentury | Jun 30, 2014
Emerging Company Profile

Biometheus: Placebo parity

...companies to exclude these patients up front and cut trial sizes in half. Last week, Biometheus...
...gene. The partners are finalizing the terms of an exclusive license agreement for the marker. Biometheus...
...Biometheus LLC , Boston, Mass. U.S. Food and Drug Administration (FDA) , Silver Spring, Md. Sidebars Biometheus LLC...
BioCentury | Jun 30, 2014
Company News

Beth Israel Deaconess, Biometheus deal

...Newco Biometheus emerged from stealth mode and announced an exclusive option from Beth Israel Deaconess Medical...
...option from Beth Israel Deaconess Medical Center to IP covering technology to detect placebo responders. Biometheus...
...to license the test to third-parties to screen patients for the polymorphism for clinical trials. Biometheus...
BioCentury | Jun 24, 2014
Company News

Biometheus debuts to screen placebo responders

...Newco Biometheus LLC (Cambridge, Mass.) emerged from stealth mode on Monday and announced an exclusive option from...
...option from Beth Israel Deaconess Medical Center to IP covering technology to detect placebo responders. Biometheus...
...license the test to third parties to screen patients for the polymorphism for clinical trials. Biometheus...
Items per page:
1 - 4 of 4
BioCentury | May 17, 2019
Financial News

Tools4Patient raises €4M to refine, expand placebo response analytics

...consider raising another round in about 18 months to support a broader expansion. Another company, Biometheus LLC...
...website has been taken down, and an inquiry to its former CEO went unreturned (see "Biometheus...
BioCentury | Jun 30, 2014
Emerging Company Profile

Biometheus: Placebo parity

...companies to exclude these patients up front and cut trial sizes in half. Last week, Biometheus...
...gene. The partners are finalizing the terms of an exclusive license agreement for the marker. Biometheus...
...Biometheus LLC , Boston, Mass. U.S. Food and Drug Administration (FDA) , Silver Spring, Md. Sidebars Biometheus LLC...
BioCentury | Jun 30, 2014
Company News

Beth Israel Deaconess, Biometheus deal

...Newco Biometheus emerged from stealth mode and announced an exclusive option from Beth Israel Deaconess Medical...
...option from Beth Israel Deaconess Medical Center to IP covering technology to detect placebo responders. Biometheus...
...to license the test to third-parties to screen patients for the polymorphism for clinical trials. Biometheus...
BioCentury | Jun 24, 2014
Company News

Biometheus debuts to screen placebo responders

...Newco Biometheus LLC (Cambridge, Mass.) emerged from stealth mode on Monday and announced an exclusive option from...
...option from Beth Israel Deaconess Medical Center to IP covering technology to detect placebo responders. Biometheus...
...license the test to third parties to screen patients for the polymorphism for clinical trials. Biometheus...
Items per page:
1 - 4 of 4